On Tuesday, Tscan Therapeutics Inc (NASDAQ: TCRX) opened lower -3.32% from the last session, before settling in for the closing price of $3.01. Price fluctuations for TCRX have ranged from $2.60 to $9.69 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 230.91%. Company’s average yearly earnings per share was noted 6.43% at the time writing. With a float of $43.51 million, this company’s outstanding shares have now reached $49.08 million.
The extent of productivity of a business whose workforce counts for 154 workers is very important to gauge. In terms of profitability, gross margin is 61.01%, operating margin of -1276.07%, and the pretax margin is -1188.88%.
Tscan Therapeutics Inc (TCRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tscan Therapeutics Inc is 18.47%, while institutional ownership is 74.34%. The most recent insider transaction that took place on Dec 13 ’24, was worth 290,140. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $2.90, taking the stock ownership to the 5,357,347 shares. Before that another transaction happened on Dec 12 ’24, when Company’s 10% Owner bought 31,800 for $3.01, making the entire transaction worth $95,629. This insider now owns 5,257,347 shares in total.
Tscan Therapeutics Inc (TCRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.43% per share during the next fiscal year.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Check out the current performance indicators for Tscan Therapeutics Inc (TCRX). In the past quarter, the stock posted a quick ratio of 9.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
The latest stats from [Tscan Therapeutics Inc, TCRX] show that its last 5-days average volume of 0.4 million was superior to 0.27 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 34.17%. Additionally, its Average True Range was 0.33.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 7.79%, which indicates a significant decrease from 13.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 146.10% in the past 14 days, which was higher than the 78.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.48, while its 200-day Moving Average is $6.28. Now, the first resistance to watch is $2.99. This is followed by the second major resistance level at $3.07. The third major resistance level sits at $3.12. If the price goes on to break the first support level at $2.85, it is likely to go to the next support level at $2.80. Assuming the price breaks the second support level, the third support level stands at $2.72.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
There are currently 53,371K shares outstanding in the company with a market cap of 155.31 million. Presently, the company’s annual sales total 21,050 K according to its annual income of -89,220 K. Last quarter, the company’s sales amounted to 1,050 K and its income totaled -29,890 K.
